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INTRODUCTION 
Primary vascular dysregulation (PVD) is defined as an inherit-
ed tendency to react inappropriately to stimuli such as cold-
ness or emotional stress, and cold extremities are the leading 
symptom.1,2 This symptom has historically been named “hie-
sho,” cold syndrome, or vasospastic syndrome; recently, it has 
been termed as PVD to reflect the fact it is a functional dysreg-
ulation of the blood vessels seen among a relatively healthy 
population.3,4 The main symptoms of PVD include thermal dis-
comfort with cold extremities, which may be accompanied by 
hypotension, headache, or tinnitus. The symptoms of PVD 
may mimic those of Raynaud’s phenomenon. However, the 
symptoms are much milder, and the triphasic color-change 
characteristically seen in Raynaud’s phenomenon is absent.5 
Although the disease clearly causes discomfort among patients, 
it is not currently considered as a disease that requires a spe-
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cific treatment. 
Currently, the treatment of PVD involves avoiding emotional 
stress and cold exposure, as well as maintaining an appropri-
ate body mass index and an intake of fruits and vegetables ab-
undant in antioxidants. Pharmacological agents used for the 
treatment of PVD include magnesium, calcium channel block-
er, endothelin antagonist, fludrocortisone, carbonic anhydrase 
inhibitor, ginkgo biloba, and others; however, there are few 
well-controlled studies regarding the effects of such agents on 
PVD, creating a need for further research.6 
Current efforts elucidating the pathophysiology of PVD sug-
gest that regulation of vascular contraction or oxidative stress 
may be a viable approach toward therapy. Ophthalmologic dis-
eases associated with PVD have shown increases in endothe-
lin-1 and resulting increases in prostaglandin E2 (PGE2), im-
plying that pharmacologic agents targeting these molecules 
may ameliorate the symptoms.6 
Triflusal (2-acetoxy-4-trifluoromethylbenzoic acid) is chem-
ically related to aspirin.7 However, in contrast to aspirin,8 it le-
aves intact the arachidonic acid pathway,9 favors the produc-
tion of nitric oxide (NO),10 and increases the concentration of 
cyclic nucleotide in endothelial cells, resulting in the expan-
sion of peripheral blood vessels. In this study, we explored the 
efficacy of triflusal on PVD, comparing it with aspirin in a dou-
ble-blind randomized crossover trial.
MATERIALS AND METHODS
Study population
This study, performed from August 2011 to October 2012, en-
rolled patients of 20 to 60 years of age who 1) visited our outpa-
tient clinic for symptoms of microcirculation impairment or 2) 
saw the advertisement listed in newspapers. PVD was defined 
as a combination of a score greater than 7 points in a validated 
questionnaire [10-question interview: subject selection symp-
tom score (SSS score)]3 and an abnormal result of a local cold 
exposure test on nail fold capillaroscopy.4,11-13 This method has 
been described in detail previously.14 Briefly, the skin of the nail 
fold was made transparent using a drop of oil. A microscope 
with a monitor coupled to a video recorder was used, allowing 
blood flow to be saved and to be analyzed. After the baseline 
flow recording, the nail fold area was cooled to 14–15°C for 60 
seconds by rapidly decompressing carbon dioxide (gas stream 
temperature, -15°C), and the occurrence and duration of cap-
illary blood flow was recorded. A flow stop time of greater than 
12 seconds was defined as a vasospastic reaction. After a de-
tailed history-taking of patients, we excluded individuals with 
a history of systemic disease (e.g., diabetes, overt peripheral ar-
tery disease, familiar hypercholesterolemia, systemic circula-
tory disease other than vasospasm). This study additionally ex-
cluded patients who were using vasodilators; pregnant or 
nursing patients; patients with bleeding tendency, thrombo-
cytopenia (platelet<100000 mm3), chronic liver disease [aspar-
tate transaminase (ALT)>100 IU/L or alanine transaminase 
(AST)>100 IU/L], or renal dysfunction (creatinine>4.0 mg/dL); 
and patients in whom the use or discontinuation of antiplate-
let agents was contraindicated. Among the 122 initially regis-
tered patients, 12 were diagnosed as not having PVD and were 
excluded, leaving 110 patients who were ultimately enrolled. 
These patients were placed into either an aspirin group or a 
triflusal group after 1:1 randomization. During the study, 22 
patients dropped out, while the remaining 88 patients com-
pleted the study. The reasons for dropout included gastrointes-
tinal symptoms such as dyspepsia or stomachache (11 patients; 
4 in aspirin group, 7 in triflusal group), occurrence of colon can-
cer (1 patient), cholecystectomy due to a gallbladder stone, for-
eign body sensation in the esophagus (1 patient), and with-
drawal of consent (9 patients).
Study design
This study proceeded in a double-blind, randomized, cross-
over design. Fig. 1 describes the overall process of the study. In 
short, the selected patients were given either triflusal (300 mg, 
b.i.d.) or aspirin (150 mg, b.i.d.) for 6 weeks. After a washout 
period of 2 weeks, the drugs were crossed over, and the pa-
tients were given the drug they had not originally received for 
6 more weeks. During each 6-week period of drug administra-
tion, the patients’ cold intolerance symptom severity (CISS) sc-
ores were measured, and finger Doppler and indocyanine 
green perfusion imaging were performed. Institutional Review 
Committee approval and informed consent were obtained, 
and all clinical investigation was conducted according to the 
principles expressed in the Declaration of Helsinki. The Clini-
calTrials.gov identifier was NCT01612273. 
Efficacy and clinical measurements
The primary endpoints were the change of CISS and the mean 
radial peak systolic velocity (PSV). To assess the subjective 
symptoms of the patients, this study employed the CISS score.15 
The CISS questionnaire was originally used to measure post-
traumatic cold intolerance; however, considering that it is a 
well-validated questionnaire that accurately reflects patients’ 
symptoms, this study used the questionnaire to assess the sub-
jective symptoms of PVD patients. Finger Doppler indices were 
measured by color Doppler ultrasound with a 7- to 15-MHz li-
near transducer using a Philips iE33 (Philips Medical Systems, 
Bothell, WA, USA). The color duplex Doppler imaging was used 
to visualize the flow, and the flow velocities were also measured 
with spectral analysis. The measured parameters were radial 
and palmar PSV and end diastolic velocity (EDV). PSV and 
EDV values were expressed as centimeters per second, and 
the intraclass correlation coefficient of radial finger Doppler 
was 88.4%.
As a secondary endpoint, indocyanine green perfusion im-
aging was performed using a system developed by Vieworks 
1229http://dx.doi.org/10.3349/ymj.2015.56.5.1227
Sanghoon Shin, et al.
(Seongnam, Korea). In total, 120 images (748×518 pixels) of 
both hands were taken at 5-s intervals for 8 min immediately 
after an intravenous bolus injection of indocyanine green (0.2 
mg/kg). A time-series analysis of indocyanine green fluores-
cence was then performed and translated into the perfusion 
rates of each pixel. The perfusion rate (%/min) was defined as 
the fraction of blood exchanged per min in the vascular vol-
ume. The perfusion rate of each pixel was represented in a per-
fusion map as a color-coded picture, and the distributions of 
the pixel perfusion rates in each hand were expressed as a his-
togram. Additionally, for assessment of the exploratory end-
points, Endothelin-1 levels were also measured by ELISA kits 
according to the manufacturer’s specifications (Neogen Corp., 
Lexington, KY, USA). 
Safety 
Clinical evaluations and laboratory measurements, including 
serum chemistry, urinalysis, and hematology were performed 
at selected visits. All clinical and laboratory adverse experi-
ences and concomitant medication use were recorded. 
Safety and tolerance were evaluated by reviewing all safety 
variables including clinical adverse events, laboratory test re-
sults, and vital signs. Serious adverse events were immediately 
reported regardless of the investigator’s assessment of a causal 
relationship to the study drugs, and all events were recorded 
for each subject. 
Sample size calculation and statistical analysis
No study thus far has investigated the change in microcircula-
tion with the use of triflusal. However, according Campia, et 
al.,8 the use of aspirin reduces forearm blood flow by 0.5 mL/
min/dL, and we hypothesized that triflusal would not result 
in the reduction of blood flow caused by aspirin. Based on this 
hypothesis, in a crossover design in which a p value of less than 
0.05 was considered to be statistically significant, a two-tailed 
test observing a significant difference with 90% probability 
would require a total of 87 patients. After accounting for a 20% 
drop-out rate, approximately 110 patients were determined to 
be needed.
RESULTS
The baseline characteristics of the patients are summarized in 
Table 1. In short, the mean age of the patients was 56 years, 
and the proportion of females was 53%. The two groups did 
not show a significant difference in SSS scores during screen-
ing (8.4±1.2 vs. 8.5±1.2; p=0.675) or baseline CISS (63.7±9.9 vs. 
64.4±12.0; p=0.783). The two groups also showed similar Dop-
pler parameters, including radial PSV, radial EDV, palmar PSV, 
and palmar EDV. Indocyanine green perfusion scans were also 
not significantly different between the two groups (Table 2). 
Primary endpoints
The use of triflusal significantly reduced CISS by week 6 (64.4± 
12.0 vs. 47.4±16.1; p<0.001), and the reduction was also observ-
ed after crossover from aspirin to triflusal (55.9±12.0 vs. 41.5± 
20.2; p<0.001) (Table 3). The use of aspirin also improved CISS 
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Fig. 1. Study design. This study was a double-blind, randomized, crossover design. The selected patients were given either triflusal or aspirin for 6 weeks. 
After a washout period of 2 weeks, the drugs were crossed over, and the patients were given the drug they had not received for 6 more weeks. CISS, 
cold intolerance symptom severity; PSV, peak systolic velocity; ICG, indocyanine green.
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by week 6; however, no further improvement was seen after 
crossover from triflusal to aspirin. Overall, the use of triflusal re-
sulted in a significantly greater improvement in symptoms com-
pared to aspirin (44.5±18.4 vs. 51.9±16.2; p<0.001) (Fig. 2A). 
Radial PSV significantly increased from baseline after 6 
weeks of triflusal administration (58.3±18.2 vs. 67.3±17.6; p< 
0.001). However, aspirin also showed elevated radial PSV (58.8± 
15.6 vs. 64.9±16.7; p=0.012), and no difference between the tri-
flusal and aspirin groups was observed at 6 weeks (67.3±17.6 
vs. 64.9±16.7; p=0.506). However, while the patients who crossed 
over from aspirin to triflusal showed a significant increase in 
radial PSV by week 14 (64.9±16.7 vs. 74.1±19.0; p<0.001), those 
who crossed over from triflusal to aspirin did not show an ad-
ditional increase in radial PSV (67.3±17.6 vs. 67.5±19.3; p=0.936). 
The triflusal group did not show a greater increase in radial PSV 
compared to the aspirin group at week 6 or week 14; however, 
after combining the two results, the triflusal group did show a 
significant increase in radial PSV compared to the aspirin gr-
oup (69.8±17.2 vs. 66.1±16.4; p=0.011) (Fig. 2B).
Secondary endpoints
An increase in the indocyanine green perfusion rate compar-
ed to baseline was observed in both the triflusal and aspirin 
groups. However, the perfusion rates at week 6 were not signif-
Table 1. Baseline Characteristics
n=88 Aspirin-triflusal (n=43) Triflusal-aspirin (n=45)
p value
Mean±SD or n (%) Mean±SD or n (%) Mean±SD or n (%)
Age, yrs 56.0±8.2 55.7±8.2 56.2±8.3 0.787
Female, n (%) 47 (53.4) 22 (48.8) 26 (43.5) 0.612
SBP, mm Hg 128±14 128±14 127±14 0.763
DBP, mm Hg 82±11 82±10 81±12 0.620
HR, /min 69±10 69±11 68±10 0.674
BMI, kg/m2 22.0±3.0 22.0±3.2 21.8±2.8 0.736
Hypertension, n (%) 19 (21.6) 10 (23.3) 9 (19.6) 0.671
Hyperlipidemia, n (%) 21 (23.9) 13 (30.2) 8 (17.4) 0.154
Smoking, n (%) 0.795
Never 59 (67.0) 29 (67.4) 30 (66.7)
Ex-smoker 26 (29.5) 12 (27.9) 14 (31.1)
Current smoker 3 (3.4) 2 (4.7) 1 (2.2)
Total cholesterol, mg/dL 190±32 192±33 191±35 0.916
Triglyceride, mg/dL 95±49 103±55 87±42 0.115
HDL, mg/dL 56±13 55±12 57±14 0.517
LDL, mg/dL 111±27 115±29 109±28 0.382
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein.
Data are expressed as mean±SD or n (%). 
Table 2. Baseline Value of Symptom Score, Doppler Parameter Indices, and Indocyanine Green Perfusion Scans
Aspirin-triflusal (n=43) Triflusal-aspirin (n=45) p value
SSS score, points 8.4±1.2 8.5±1.2 0.675
CISS score, points 63.7±9.9 64.4±12.0 0.783
Doppler parameter, cm/s
Right radial PSV 58.8±15.6 58.3±18.2 0.881
Left radial PSV 58.8±17.0 59.0±18.4 0.960
Right radial EDV 11.0±7.8 10.0±8.6 0.551
Left radial EDV 11.3±8.8 10.4±9.7 0.649
Right palmar PSV 34.6±11.8 33.1±14.4 0.586
Left palmar PSV 33.6±13.2 31.2±14.7 0.438
Right palmar EDV 10.9±7.5 10.9±9.3 0.985
Left palmar EDV 11.3±8.8 8.8±7.5 0.273
Indocyanine green perfusion scan, %/min
Right hand 46.0±28.2 38.0±26.8 0.175
Left hand 46.4±28.9 38.7±28.2 0.206
SSS score, subject selection symptom score according to 10-question interview; CISS score, cold intolerance symptom severity score; PSV, peak systolic velocity; 
EDV, end diastolic velocity.
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icantly different between the two groups (49.4±26.6 vs. 50.2± 
26.5; p=0.876). After crossover, the aspirin-triflusal group show-
ed a sustained increase in perfusion, while the triflusal-aspirin 
group perfusion rate decreased. By week 14, indocyanine green 
perfusion rates were significantly different between the two 
groups (54.0±27.4 vs. 41.1±24.5; p=0.022). Overall, the use of tri-
flusal resulted in a clear increase in perfusion rate compared 
to the use of aspirin (51.6±26.9 vs. 45.6±25.8; p=0.020); howev-
er, when aspirin was used, there was no significant increase in 
perfusion rate compared to baseline (42.2±14.7 vs. 45.6±25.8; 
p=0.220) (Fig. 2C).
Exploratory endpoints
Plasma endothelin-1 levels also showed a trend similar to ra-
dial PSV and CISS. Both triflusal and aspirin reduced plasma 
endothelin-1 levels compared to baseline by week 6, although 
the former resulted in a greater reduction (0.77±0.28 vs. 0.99± 
0.40; p=0.004), and overall, plasma endothelin-1 was maintain-
ed at a lower level in the triflusal group than in the aspirin group 
(0.78±0.32 vs. 1.02±0.37; p<0.001) (Fig. 2D). 
Safety and adverse events evaluation
A total of 11 patients were withdrawn due to adverse events re-
ported during this study (aspirin: 4; triflusal: 7). There were 40 
cases of reported adverse events (from these, 13 were related 
to aspirin, and 27 were associated to triflusal) in 37 subjects 
during treatment. The most frequently reported adverse events 
were dyspepsia (12 cases related to aspirin, 24 cases related to 
triflusal) and esophageal irritation (1 case related to aspirin, 3 
cases related to triflusal). All adverse events were of mild or 
moderate intensity, and all subjects recovered.
DISCUSSION
The importance of this study can be seen in three aspects. 
First, this study is the first to have attempted a pharmaceutical 
therapy to improve the symptoms of cold extremities in PVD 
patients. Second, this study found that triflusal is beneficial in 
improving cold extremities of PVD patients and that treatment 
results in greater improvement of microcirculation and symp-
toms than the use of aspirin (a representative case is shown in 
the Supplementary Fig. 1, only online). Lastly, this study also 
demonstrated a change in a biomarker–specifically, a decrease 
in endothelin-1, which results from decreased inflammation–
along with the aforementioned beneficial effects, which may 
serve as an explanation of the mechanism. 
PVD should be separated from other diseases such as mi-
crovascular complications of diabetes mellitus or small vessel 
diseases, despite the fact that they share similar pathophysiol-
ogy affecting blood flow. Particularly, if a vascular dysregula-
tion is due to diseases that can lead to increased ET-1 plasma 
levels, it needs to be classified as a secondary vascular dysreg-
ulation. Furthermore, small vessel diseases should not be con-
fused with secondary vascular dysregulation.6,16 PVD has been 
reported to occur in up to 30% of the otherwise-healthy popu-
lation aged 20 to 40 years. It also occurs more often in females 
than in males and in thin subjects more than in obese sub-
jects,17 as well as in academics more than in blue-collar work-
ers and in Asians more than in Caucasians. The main signs are 
arterial hypotension and cold extremities with an increased 
response to coldness.18 In addition, patients often indicate al-
tered drug sensitivity (partly due to altered expression of ATP-
binding cassette proteins),19 decreased sensations of thirst12 
(ET-1 increases the PGE2 level in the center of thirst), migrai-
nes, and prolonged sleep onset time.13 These symptoms result 
in a decreased quality of life and problems with everyday life. 
In addition, there have been reports suggesting PVD as a pre-
disposing factor of normal tension glaucoma, myocardial in-
farction, and cerebral infarction.4 However, PVD is not consid-
ered a disease entity as of yet; therefore, treatment for this con-
dition is not indicated in all cases. Patients with PVD are ge-
nerally in good health and do not require a specific treatment. 
However, treatment may be considered if the patient has PVD-
Table 3. Primary and Secondary Endpoints of Pre-Crossover, Post-Crossover, and Combined
n Aspirin n Triflusal p value
CISS score, point
Pre-crossover 43 55.9±12.0 45 47.3±16.3 0.006
Post-crossover 45 48.0±18.6 43 41.5±20.2 0.118
Combined 88 51.9±16.2 88 44.5±18.4 <0.001
Radial mean PSV, cm/s
Pre-crossover 43 65.1±15.2 45 67.3±16.2 0.506
Post-crossover 45 67.1±17.6 43 72.5±16.6 0.143
Combined 88 66.1±16.4 88 69.8±17.2 0.011
Indocyanine green perfusion scan, %/min
Pre-crossover 43 50.2±26.5 45 49.4±26.6 0.876
Post-crossover 45 41.1±24.5 43 54.0±27.4 0.022
Combined 88 45.6±25.8 88 51.6±26.9 0.020
CISS score, cold intolerance symptom severity score; PSV, peak systolic velocity.
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Fig. 2. Primary, secondary, and exploratory endpoints. (A) Although the CISS scores of Aspirin and Triflusal groups both decreased by week 6, only 
the CISS score of Triflusal group decreased further by week 14 after cross-over, while that of Aspirin group remained unchanged. Overall, both Aspi-
rin and Triflusal were effective in relieving symptoms, but Triflusal group had significantly more improved symptoms compared with Aspirin group. (B) 
Although radial PSV was increased in both Aspirin and Triflusal groups by week 6, it was increased further only in Triflusal group by week 14 after 
cross-over while the Aspirin group showed no further change. Overall, although both Aspirin and Triflusal groups had increased radial PSV, the Triflu-
sal group showed a more significantly increased PSV compared with Aspirin group. (C) ICG perfusion scan was significantly increased in the group 
that was treated with Triflusal compared with baseline or those treated with Aspirin. (D) ET-1 was significantly decreased in Triflusal group compared 
with Aspirin group by week 6, and this significant decreased was also observed after the cross-over. CISS, cold intolerance symptom severity; PSV, 
peak systolic velocity; ICG, indocyanine green.
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related disease or if the symptoms result in difficulty perform-
ing daily activities. The side effects of the treatment agents need 
to be weighed against the expected benefits. Drugs such as 
magnesium, calcium channel blocker, and gingko biloba, wh-
ich are relatively inexpensive and safe, may lead to an improved 
quality of life resulting from symptom relief. However, it may 
be difficult to recommend agents such as bosentan or fludro-
cortisone due to their potential side effects.6
Triflusal is an antiplatelet agent with structural similarities 
to salicylates, though it is not a derivative of aspirin. Triflusal has 
a dose-dependent inhibitory effect on platelet aggregation, and 
the most effective dosage for a platelet anti-aggregation effect 
is 600 mg/day.20 It has an efficacy similar to aspirin in patients 
with cerebral or myocardial infarction. In several large-scale, 
randomized, double-blind, multicenter studies including 2113 
patients with non-disabling ischemic stroke or a transient isch-
emic attack in the previous 6 months, triflusal 600 mg/day was 
equally as effective as aspirin 325 mg/day, as evident from the 
incidence of the primary composite endpoint of serious vascu-
lar events (12.7% vs. 13.1%).21 The Triflusal in Myocardial In-
farction (TIM) study also revealed no significant difference 
between triflusal and aspirin in the occurrence of the compos-
ite primary endpoint of death, nonfatal myocardial reinfarc-
tion, or nonfatal cerebrovascular events within 35 days of acute 
myocardial infarction (9.1% vs. 10.2%).22 Therefore, triflusal is 
an antiplatelet agent that can replace aspirin.
Triflusal, despite its structural analogy to aspirin, exhibits dis-
tinct pharmacological, pharmacokinetic, and biochemical pro-
perties.23 When compared to aspirin, several potential benefi-
cial effects can be expected from triflusal. In patients with type 
1 diabetes, serum levels of thromboxane B2 were greatly reduc-
ed with both triflusal and aspirin after 15 days (by 85% and 99%, 
respectively; p<0.05). However, reductions in serum 6-keto-
prostaglandin-F 1α levels were negligible with triflusal com-
pared with aspirin (8.8% vs. 97.8%; p<0.001).9 These data sug-
gest that triflusal has selective activity for platelet arachidonic 
acid metabolism, whereas aspirin inhibits both platelet and 
vascular endothelial arachidonic acid metabolism. Triflusal 
also exerts multiple effects on platelet adhesion and aggrega-
tion.24 Although it inhibits platelet prostaglandin G/H-synthase, 
triflusal is a weaker inhibitor than aspirin; therefore, it does 
not significantly reduce prostacyclin synthesis by endothelial 
prostaglandin G/H-synthase.25 Both triflusal and its main ac-
tive metabolite, 3-hydroxy-4-trifluoro-methylbenzoic acid, in-
hibit degradation of platelet and endothelial cyclic adenosine 
monophosphate, which subsequently limits intracellular calci-
um mobilization and platelet-endothelial cell interactions.24,26 
They also inhibit prostaglandin G/H-synthase-2 expression 
while activating transcription factor nuclear factor (NF)-kB and 
NF-kB-induced inflammatory mediators, such as vascular cell 
adhesion molecule-1.27 One study reported that triflusal inhib-
its nuclear factor of activated T-cells (NFAT)-mediated tran-
scription at a therapeutically relevant concentration, while as-
pirin inhibits NFAT transactivation only at a high concentr-
ation.28 Moreover, triflusal enhances NO synthesis in neutro-
phils, leading to an increased vasodilatory potential.29 A recent 
in vitro study found that administration of endothelin-1 in 
APP23 transgenic mice triggered endothelin-induced isch-
emia along with increases in Alzheimer’s disease pathological 
markers in the region of the infarct, and triflusal reduced in-
flammation surrounding the endothelin-induced infarct.30 It 
appears that the vasodilation effect, anti-inflammatory effect 
of triflusal, and prevention of vasoconstriction caused by endo-
thelin-1 ameliorates symptoms of PVD and improved blood 
circulation.
 
Limitation
The limitations of this study are as follows. First, this study be-
gan under the assumption that aspirin results in vasoconstric-
tion.8 However, consistent administration of aspirin actually 
resulted in vasodilation instead of vasoconstriction. While this 
is difficult to explain, a possible mechanism is that aspirin ini-
tially causes vasoconstriction yet results in vasodilation when 
used long-term by improving endothelial function.31 Second, 
this was a single center study performed mainly on Asians, 
which creates difficulty in generalizing the conclusion. Third, 
there were seasonal variations within the duration of this study, 
and the differences in climate may have affected the subjective 
reactions of PVD patients. However, this seasonal effect was 
shared by all patients, and we believe it did not greatly affect 
the objective parameters. Fourth, the incidence of dyspepsia 
was relatively high during triflusal use in this study. However, 
the rate was similar to previous reported adverse events [27.4% 
in the Triflusal versus Acetylsalicylic Acid in Secondary Pre-
vention of Cerebral Infarction (TACIP) study].21 Lastly, addi-
tional studies are needed for patients who are unreactive to 
the drugs. Regardless of these limitations, however, it was 
clearly demonstrated that triflusal is superior to aspirin in in-
creasing peripheral blood flow and in ameliorating symp-
toms.
Conclusion
This study presented data of subjective symptoms and objec-
tive parameters obtained using a double-blind, randomized, 
crossover design, which suggests that triflusal provides greater 
beneficial effects to PVD patients than aspirin. It also demon-
strated a decrease in endothelin-1 during the use of triflusal to 
explain this beneficial phenomenon. Therefore, triflusal may be 
considered as a first-line treatment in patients with symptoms 
of PVD who are using aspirin. 
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